Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/30/2025

Negative Chronotropic Medications for Heart Failure and Post-Myocardial Infarction

First-Line Beta-Blockers

  • The European Society of Cardiology recommends beta-blockers as the first-line negative chronotropic agents for heart failure with reduced ejection fraction (HFrEF) and post-myocardial infarction, with bisoprolol, carvedilol, and metoprolol succinate being the only evidence-based options that reduce mortality by at least 20% 1, 2
  • The American College of Cardiology and European Heart Association suggest that beta-blockers should be initiated in all stable patients with NYHA Class II-IV heart failure and LVEF <40% on background therapy with ACE inhibitors/ARBs and diuretics, reducing all-cause mortality by 30%, cardiovascular death, sudden cardiac death, and heart failure hospitalizations by 35% 1, 4
  • Benefits of beta-blockers are consistent across age, gender, functional class, and ischemic versus non-ischemic etiology 4

Clinical Context

  • Long-term beta-blockade is recommended in addition to ACE inhibition for all patients with left ventricular systolic dysfunction following acute MI to reduce mortality, using beta-1 selective agents (bisoprolol, metoprolol succinate) or carvedilol (beta-1 and alpha-1 blocker) 4, 5, 6, 7, 8
  • Patients must be relatively stable without intravenous inotropic support or marked fluid retention before starting beta-blockers, with a step-by-step initiation protocol to avoid decompensation 4, 9

Second-Line and Third-Line Options

  • Ivabradine is a selective If-channel blocker reserved for patients who remain symptomatic despite maximally tolerated beta-blocker therapy, with specific indications for patients with HFrEF (LVEF ≤35%), sinus rhythm, and heart rate ≥70 bpm despite maximally tolerated beta-blocker dose 2
  • Digoxin provides negative chronotropic effects primarily in atrial fibrillation but has no mortality benefit in sinus rhythm, with specific use cases for atrial fibrillation with any degree of symptomatic heart failure, and sinus rhythm with persistent symptoms 5, 6, 10

Dosing and Monitoring

  • Target doses for beta-blockers are evidence-based and should be achieved through titration, with monitoring for worsening heart failure symptoms, fluid retention, hypotension, and symptomatic bradycardia at each visit 1, 2, 9
  • Women require lower serum digoxin concentrations (≤0.9 ng/mL) to avoid increased mortality, with higher concentrations (≥1.2 ng/mL) increasing mortality in both sexes 10

REFERENCES